Bioqual

What Bioqual does

BIOQUAL, Inc. is a publicly traded preclinical contract research organization (CRO) founded in 1981 and headquartered in Rockville, Maryland, listed on OTC Markets under the symbol BIOQ. The company provides in vivo animal model studies, in vitro laboratory services, and IND-enabling preclinical research to biopharmaceutical companies, government agencies (notably the NIH), and academic institutions. Core research areas include infectious diseases, immunogenicity, and oncology, with infrastructure spanning five Rockville-area locations housing 2,400+ non-human primates, 8,000+ mice, and 800+ ferrets.

BIOQUAL operates BSL-3 biocontainment laboratories with select agent standards, supporting work on high-priority pathogens including HIV, influenza, SARS-CoV-2, malaria, Zika, Chikungunya, Dengue, and orthopox viruses. The service portfolio spans immunoassay platforms (ELISA, Western Blot, Flow Cytometry, Luminex, ELISpot, PRNT, microneutralization), pathogen-specific animal models, custom model development, imaging services, and GLP-compliant toxicology and pharmacokinetic studies. The company holds AAALAC accreditation, OLAW assurance, and USDA Class R Research Facility registration, providing regulatory-compliant pathways supporting FDA IND submissions. ECOVADIS 'Committed' recognition (October 2025) and Scientist.com Supplier Recognition (2025) add ESG and marketplace credentials.

The company's preclinical work has supported FDA approvals for Moderna's and Johnson & Johnson's COVID-19 vaccines, Eli Lilly's and Regeneron's COVID-19 monoclonal antibodies, and Gilead's Lenacapavir for HIV prevention. BIOQUAL generates revenue through fee-for-service contract research engagements with NIH, academic institutions, and commercial biopharmaceutical sponsors via a quote-based pricing model, consultative enterprise sales motion, and outreach through scientific conferences, peer-reviewed publications, and academic partnerships with institutions including the University of Pennsylvania, Harvard, Duke, and the University of California system. Leadership comprises President/CSO Dr. Hanne Andersen Elyard (appointed October 2025), COO Mitch Franklin, CFO Chris Kirk, and VP of Operations Jim Treece.

Name

Bioqual

Legal name

BIOQUAL, Inc.

Website

https://bioqual.com

Company type

Public

Founded year

1981

Operating status

Operating

Headcount range

101–250 employees

Short description

BIOQUAL is a publicly traded preclinical contract research organization founded in 1981 in Rockville, Maryland, providing animal model studies, BSL-3 biocontainment, immunoassays, and IND-enabling services to biopharmaceutical companies, government agencies, and academic institutions.

Ownership category

akta.pro rank

Product category

Contract Research Organization (Preclinical CRO)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Cell-Based & Potency Assays (Bioassays) (HLAGADAH)

akta.pro secondary industries

Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM), Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK)

Keywords

• Preclinical contract research
• Infectious disease research
• Non-human primate models
• Immunogenicity testing
• Animal model studies

Headquarters

HQ city

Rockville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Research Services: BIOQUAL generates revenue through fee-for-service contract research engagements with government agencies, academic institutions, and commercial biopharmaceutical companies for preclinical testing services including animal model studies, immunoassays, and IND-enabling studies.
2. Government Contracts: Revenue from government contracts, primarily with NIH, for preclinical research services supporting vaccine and therapeutic development.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

BIOQUAL is a preclinical contract research organization (CRO) that provides animal model studies (non-human primates, mice, ferrets, rabbits, hamsters, guinea pigs), in vitro laboratory services including immunoassays, and IND-enabling studies. It specializes in infectious disease (HIV, influenza, SARS-CoV-2, malaria, Zika, Dengue), oncology, and immunogenicity research, operating BSL-3 biocontainment facilities with select agent capabilities to support biopharmaceutical, government, and academic clients through FDA submission pathways.

Product overview

BIOQUAL is a preclinical Contract Research Organization (CRO) offering a comprehensive portfolio of research services. The company provides integrated infectious diseases research, immunogenicity testing, and oncology research services, supported by small and large animal models (including NHPs) and in vitro lab services. Additional specialized offerings include BSL3 biocontainment, imaging services, custom animal model development, and IND-enabling services. The product portfolio is structured as a unified service platform where animal models, laboratory testing, and specialized capabilities work together to support drug development from early research through preclinical testing for IND submissions.

Differentiator

Problem solved

Functional benefit

Products and services

• Infectious Diseases Research Services Comprehensive preclinical research services for infectious diseases including assay development, pathogen-specific studies, and advanced animal models for viral (HIV, influenza, SARS-CoV-2, RSV, Zika, Chikungunya, Dengue, HSV, orthopox), bacterial (S. aureus, C. difficile, M. tuberculosis), and parasitic (malaria) pathogens. For biopharmaceutical, government, and academic clients developing vaccines and therapeutics.
• Immunogenicity Services Immunogenicity testing services including animal models for vaccine immunogenicity testing, neutralizing antibody assays, immune response profiling, and tailored assay development for proteins, antibodies, gene therapies, and cell therapies. For vaccine and biologic developers requiring preclinical immunogenicity data.
• Oncology Research Services Preclinical oncology research including in vitro and in vivo cancer models, tumor xenografts, drug efficacy testing, combination therapy studies, immune response studies, and toxicology and safety testing. For oncology drug developers.
• Small Animal Models Small animal models including inbred mouse strains (C57BL/6, BALB/c), knockout mice, transgenic and humanized mice, xenograft and immunodeficient models, as well as rats, rabbits, hamsters, and guinea pigs for various research applications. Housing capacity for 8,000+ mice.
• Large Animal Models (NHP) Non-human primate (NHP) models including rhesus macaques, cynomolgus macaques, African green monkeys, and marmosets for advanced research including infectious disease studies, pharmacology, and toxicology, with customized research solutions. Housing capacity for 2,400+ NHPs plus 800+ ferrets.
• Lab Services (In Vitro) In vitro laboratory services including cell-based assays, immunoassays (ELISA, Western Blot, Flow Cytometry, Luminex, ELISpot, PRNT, Microneutralization, HAI), toxicity and cytotoxicity testing, viral load testing (qRT-PCR, TCID50, plaque assay), and tailored assay development.
• Advanced Biocontainment (BSL-3) Services State-of-the-art Biosafety Level 3 (BSL-3) facilities with select agent capabilities for working with high-risk pathogens and conducting infectious disease research under the highest safety standards.
• Imaging Services Advanced imaging capabilities for preclinical studies providing detailed insights into mechanisms of action, therapeutic efficacy assessment, and complex biological interactions.
• Animal Model Development Custom animal model development services tailored to unique research program needs, focusing on reproducibility and translational relevance with models that mimic disease conditions and therapeutic responses.
• IND-Enabling Services Comprehensive support for the Investigational New Drug (IND) process including toxicology studies, pharmacokinetic profiling, GLP services, and regulatory documentation for streamlined progression from preclinical research to clinical trials.

Quantifiable outcome

• Supported FDA approvals for COVID-19 vaccines from Moderna and Johnson & Johnson
• +2 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

14 partnerships are on record, tiered core and minor.

• University of PennsylvaniacoreStrategic or Co-development PartnerAcademic partnership for collaborative research, joint studies, and access to cutting-edge research facilities. Partnership includes support for collaborative publications and funding opportunities for innovative research projects.
• Harvard UniversitycoreStrategic or Co-development PartnerAcademic partnership for collaborative research and joint studies in life sciences. Partnership provides access to research facilities and supports collaborative publications.
• Duke UniversitycoreStrategic or Co-development PartnerAcademic partnership for collaborative research and joint studies in infectious disease and immunology research areas.
• Temple UniversitycoreStrategic or Co-development PartnerAcademic partnership for collaborative research in biomedical sciences with shared goals of advancing scientific understanding.
• Drexel UniversitycoreStrategic or Co-development PartnerAcademic partnership for collaborative research in biomedical and life sciences research areas.
• Rutgers UniversitycoreStrategic or Co-development PartnerAcademic partnership supporting collaborative research and joint studies in scientific research areas.
• University of WisconsincoreStrategic or Co-development PartnerAcademic partnership for collaborative research and joint studies in life sciences.
• University of California SystemcoreStrategic or Co-development PartnerAcademic partnership across UC campuses for collaborative research and joint studies.
• Tulane UniversitycoreStrategic or Co-development PartnerAcademic partnership for collaborative research in biomedical sciences.
• University of Alabama at BirminghamcoreStrategic or Co-development PartnerAcademic partnership for collaborative research and joint studies in infectious disease research.
• University of North CarolinacoreStrategic or Co-development PartnerAcademic partnership for collaborative research and joint studies in biomedical research.
• University of MinnesotacoreStrategic or Co-development PartnerAcademic partnership for collaborative research and joint studies in life sciences.
• Virginia TechcoreStrategic or Co-development PartnerAcademic partnership for collaborative research and joint studies in scientific research areas.
• Montgomery College FoundationminorOthersPartnership providing the John C. Landon Memorial Scholarship and John C. and Nancy B. Landon Memorial Endowed Scholarship to support students pursuing careers in life sciences. Named in honor of BIOQUAL's late founder.

Scale indicators7 records

Expansion highlights5 records

Broad incumbents

• PPD (Thermo Fisher Scientific): Global CRO (acquired by Thermo Fisher) offering preclinical and clinical research services, comparable as a broad incumbent serving the same biopharma customers as BIOQUAL.
• IQVIA: Largest clinical and life sciences services provider with preclinical capabilities; overlaps with BIOQUAL in serving biopharma R&D but at vastly larger scale.
• Labcorp (Covance/Fortrea): Major CRO with extensive preclinical and clinical service offerings; competes for the same biopharma sponsors as BIOQUAL but as part of a much broader diagnostic and drug development portfolio.
• Charles River Laboratories: Largest preclinical CRO with deep NHP, BSL, and IND-enabling capabilities; competes with BIOQUAL for biopharma preclinical study work but at far greater scale and global footprint.

Others

• Envigo (Inotiv): Research models and preclinical services provider (now part of Inotiv) directly comparable to BIOQUAL's animal model and research services offerings.

Direct peers

• Taconic Biosciences: Specialized provider of genetically engineered mouse and rat models plus related research services, closely overlapping with BIOQUAL's small animal models and immunogenicity offerings.
• Inotiv: Preclinical CRO and research models provider offering animal models (including NHPs), surgical services, and contract research directly comparable to BIOQUAL's integrated preclinical service platform.

Emerging players

• The Jackson Laboratory: Non-profit research institute supplying mouse models and preclinical research services to academic and biopharma clients, comparable to BIOQUAL on the small-animal research models side.
• Wuxi AppTec: Global preclinical CRO with strong NHP infectious disease capabilities that competes for the same biopharma sponsors as BIOQUAL, particularly in North America and Europe.
• Pharmaron: Preclinical CRO offering in vivo pharmacology, toxicology, and IND-enabling services with growing U.S. presence; directly comparable to BIOQUAL's preclinical drug development service stack.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/bioqual-inc

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioqual